Among individuals with schizophrenia, the risk for natural-cause mortality was increased in those with reduced cognitive functioning.

The unique stress that older mothers of vulnerable adult children experience over the holidays is often overlooked. Here's ...

People who land in the ER for psychedelic use are at significantly higher risk of schizophrenia, according to an eye-opening ...

Individuals with emergency department visits involving hallucinogen use are at high risk of developing schizophrenia, ...

Even after controlling for a person’s existing substance use and mental health disorders, there remained a 3.5-fold increased ...

On Monday, the pharma giant announced that two mid-stage trials of a schizophrenia treatment — added through ... in a note ...

AbbVie Inc. shares fell the most in three years after two mid-stage trials of its drug to treat schizophrenia failed to meet ...

Shares of AbbVie (ABBV) are sliding on Monday after the company’s drug candidate for schizophrenia failed to meet the key goal in two ...

AbbVie reports disappointing mid-stage data for its schizophrenia drug. Jason Snipe of Odyssey Capital still likes AbbVie ...

The shocking failure of AbbVie’s emraclidine has investors questioning the Big Pharma’s long-term neuroscience strategy, ...

Bristol Myers Squibb stock rocketed Monday after AbbVie's experimental schizophrenia treatment failed in a pair of midstage studies.

AbbVie said on Monday that an experimental schizophrenia drug it gained through an $8.7 billion deal for Cerevel Therapeutics failed two mid-stage studies, sending the drugmaker's shares plunging 12.5 ...